Showing 7571-7580 of 10035 results for "".
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- Study: Strontium Cream Could Help Manage Pruritus in HShttps://practicaldermatology.com/news/Study-Strontium-Cream-Could-Help-Manage-Pruritus-HS/2475142/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to new research published in the Journal of Clinical and Aesthetic Dermatology. Statistical analysis of baseline and 1-week post-intervention surveys amon
- Skin Cancer Champions Launches New Sitehttps://practicaldermatology.com/news/Skin-Cancer-Champions-Launches-New-Site/2475125/Skin Cancer Champions announced the launch of a new website, skincancerchampions.org, aimed at making it easier for patients to find what they need, engage with resources, and help more people discover the community. “Our new site is a step forward in making our community more accessible,
- Study: Belly Fat More Predictive of Psoriasis Than Overall Body Fathttps://practicaldermatology.com/news/study-belly-fat-more-predictive-of-psoriasis-than-overall-body-fat/2475108/Central adiposity—particularly abdominal fat—is more strongly linked to psoriasis risk than overall body fat, according to a new analysis published in the Journal of Investigative Dermatology.
- Study: Lotion Shows Efficacy in Treating Hyperkeratotic Plaque Psoriasishttps://practicaldermatology.com/news/hptaz-lotion-shows-efficacy-in-treating-hyperkeratotic-plaque-psoriasis/2475106/HP/TAZ lotion significantly improved hyperkeratotic psoriatic plaques in subgroups, according to recent data from a post hoc analysis of phase 3 trials. The authors of the post hoc analysis pooled data from two eight-week, v
- INTEGUMENT-INFANT to Test Roflumilast Cream in Children Under Twohttps://practicaldermatology.com/news/integument-infant-to-test-roflumilast-cream-in-children-under-two/2475087/Arcutis Biotherapeutics has announced the enrollment of the first participants in its new phase 2 INTEGUMENT-INFANT study focusing on the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis (AD).
- Patent Issued for Coya’s IL-2 Technologyhttps://practicaldermatology.com/news/patent-issued-for-coyas-il-2-technology/2474992/Coya Therapeutics has received a new U.S. patent for proprietary methods of producing a highly stable liquid formulation (aldesleukin) of recombinant human interleukin-2 (rhIL-2), according to a press release from the manufacturer.
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- From WHA78: Skin Diseases Are a Global Public Health Priorityhttps://practicaldermatology.com/news/wha78-skin-diseases-are-a-global-public-health-priority/2474881/In what was termed a historic decision at the 78th World Health Assembly (WHA78) in Geneva, Member States unanimously adopted a resolution declaring skin diseases a global public health priority, according to a press statement.